Action LGND LIGAND PHARMACEUTICALS INCORPORATED
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Ligand Pharmaceuticals Incorporated

Actions

LGND

US53220K5048

Temps réel estimé Cboe BZX
Autres places de cotation
 15:32:51 08/05/2024 		Varia. 5j. Varia. 1 janv.
73,14 USD -0,11% Graphique intraday de Ligand Pharmaceuticals Incorporated +4,76% +2,52%
07/05 Transcript : Ligand Pharmaceuticals Incorporated, Q1 2024 Earnings Call, May 07, 2024
07/05 Ligand Pharmaceuticals Incorporated réaffirme ses prévisions de résultats pour l'année 2024 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Ligand: Q1 Earnings Snapshot
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Posts Q1 Revenue $31M, vs. Street Est of $27.9M
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q1 EPS $1.20, vs. Street Est of $0.83
Ligand Reports First Quarter 2024 Financial Results
Ligand Pharmaceuticals Incorporated Reaffirms Earnings Guidance for the Year 2024
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
Ligand Pharmaceuticals Incorporated : Certificate of Incorporation/Bylaws - Form 8-K
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
Ligand Pharmaceuticals Appoints Scott Plesha to the Role of Chief Executive Officer
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics
Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
Ligand Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ligand Pharmaceuticals' Q4 Adjusted Earnings Rise, Revenue Falls; Reaffirms 2024 Guidance
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action LGND
  4. Actualités Ligand Pharmaceuticals Incorporated
  5. Autres langues